OXON at the 12th pharmacovigilance 2017 conference
"Ensuring safer drugs to market by analysing latest developments
in pharmacovigilance, drug safety and risk management"
24/01/2017
Nawab Qizilbash, Head of OXON, will be presenting "Post marketing drug surveillance"
Drug safety representatives from the pharmaceutical industry and academics will provide insights and examples of understanding new and existing pharmacovigilance requirements and how to improve the organisations' compliance with these pharmacovigilance requirements.
Dr. Nawab Qizilbash, OXON; London School of Hygiene & Tropical Medicine; Hospital Cantoblanco, Madrid; Joint coordinator of EMA ENCePP Special Interest Group on Impact of PV Activities will:
- Present "Post marketing drug surveillance"
- Moderate the 1st Panel topic "Challenges and Opportunities - Optimize the overall PV ecosystem for maximum benefit", 2nd Panel Topic "Enhancing communications between - Sponsor- Site - CRO and Patients"Â and 3rd Panel Topic "The developing regulatory framework in advanced and developing markets"